Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Head &Neck Clear all
Completed No phase listed Observational

Influence of Nutrition and Sarcopenia on Esophageal Cancer Outcomes

NCT06314516
View directory record Official record
Conditions
Esophageal Cancer, Sarcopenia
Interventions
Not listed
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years to 90 Years
Enrollment
1,717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

NCT00176800
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
Tetrathiomolybdate (TM), Radiation, Surgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Not applicable Interventional

Routine Post-Operative Supplemental Nutrition

NCT02297607
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Tube Feeding
Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies

NCT01401907
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Small Cell Lung Cancer, Mesothelioma, Esophageal Cancer, Gastric Cancer, Liver Cancer, Pancreatic Cancer
Interventions
early palliative care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

NCT00003744
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gemcitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Burlington, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

NCT04313504
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Niraparib, Dostarlimab
Drug
Lead sponsor
Trisha Wise-Draper
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02684253
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Nivolumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Jul 24, 2026, 1:53 AM EDT
Withdrawn Not applicable Interventional

Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado

NCT04922112
View directory record Official record
Conditions
Obstructive Sleep Apnea, Squamous Cell Carcinoma of Head and Neck
Interventions
Obstructive sleep apnea testing
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

NCT01927887
View directory record Official record
Conditions
Papillary Carcinoma of Thyroid Gland, Metastatic Medullary Thyroid Cancer, Follicular Thyroid Cancer Lymph Node Metastasis
Interventions
Ferumoxytol, Nanoparticle MRI
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Results available

The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

NCT05101798
View directory record Official record
Conditions
Neoplasm, Skull Base Neoplasm
Interventions
5-Aminolevulinic acid Hydrochloride
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Phase 2 Interventional Results available

Everolimus Versus Placebo in Head and Neck Cancer

NCT01111058
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus (RAD 001), Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
17
States / cities
Miami, Florida • Chicago, Illinois • Harvey, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Phase 1 Interventional

A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies

NCT06974734
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

NCT02841748
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Pembrolizumab, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

NCT02281955
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional Results available

Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps

NCT03349034
View directory record Official record
Conditions
Head and Neck Cancer, Free Tissue Transfer
Interventions
Ropivicaine, Local Saline Infusion
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Jul 24, 2026, 1:53 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Virtual Reality Interventions for the Improvement of Depression, Anxiety and Pain in Patients With Head and Neck Cancer and Caregivers

NCT06985784
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Interview, Medical Device Usage and Evaluation, Questionnaire Administration, Virtual Technology Intervention
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Not applicable Interventional Results available

Effect of Guided Imagery for Radiotherapy-Related Distress in Patients With Head and Neck Cancer

NCT03662698
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Guided Imagery, Treatment as Usual
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 24, 2026, 1:53 AM EDT
Recruiting Phase 1 Interventional

Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)

NCT07101432
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Fludarabine, Cyclophosphamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer

NCT00193284
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Gefitinib, Docetaxel, Carboplatin, Fluorouracil
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jul 24, 2026, 1:53 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Evaluating the Use of an Informational Head and Neck Cancer Website.

NCT04268329
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Educational website
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 1Phase 2 Interventional

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck

NCT00063895
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IIIA Non-small Cell Lung Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx
Interventions
erlotinib hydrochloride, pharmacological study, pharmacogenomic studies, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Jul 24, 2026, 1:53 AM EDT
Active, not recruiting Not applicable Interventional

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
View directory record Official record
Conditions
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Interventions
Yoga, Yoga Questionnaire, Symptom Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Active, not recruiting Phase 2 Interventional

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

NCT06855212
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Cemiplimab, Cetuximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 24, 2026, 1:53 AM EDT
Completed Phase 3 Interventional Results available

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

NCT00984282
View directory record Official record
Conditions
Thyroid Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
13
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Jul 24, 2026, 1:53 AM EDT